In last trading session, Iterum Therapeutics Plc (NASDAQ:ITRM) saw 0.32 million shares changing hands with its beta currently measuring 2.43. Company’s recent per share price level of $1.49 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $51.53M. That closing price of ITRM’s stock is at a discount of -102.68% from its 52-week high price of $3.02 and is indicating a premium of 45.64% from its 52-week low price of $0.81.

For Iterum Therapeutics Plc (ITRM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.

Iterum Therapeutics Plc (NASDAQ:ITRM) trade information

Iterum Therapeutics Plc’s shares saw a change of -15.82% in year-to-date performance and have moved -0.67% in past 5-day. Iterum Therapeutics Plc (NASDAQ:ITRM) showed a performance of -1.97% in past 30-days.

1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.68M for the same. And 1 analysts are in estimates of company making revenue of 2.8M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.27% during past 5 years.

Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders

BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC is the top institutional holder at ITRM for having 66.0 shares of worth $76.0. And as of 2024-06-30, it was holding 0.0004 of the company’s outstanding shares.